Klin Farmakol Farm. 2008;22(3):110-112

Drug-induced acute pancreatitis in inflammatory bowel diseases

Ilona Vinklerová
II. interní klinika FN a LF UP Olomouc

Drug-induced acute pancreatitis is a relatively rare adverse effect of drugs on gastrointestinal system. In patients suffering inflammatory bowel diseases is incidence of acute pancreatitis higher than in general population and drug-induced pancreatic damage constitutes an important cause of this complication. The most threatened patients seems to be females suffering Crohn`s disease, the most dangerous drugs being azathioprine and mesalazine. The risk of other drugs is significantly lower.

Keywords: Key words: drug adverse effects, acute pancreatitis, Crohn disease, ulcerative colitis.

Published: January 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vinklerová I. Drug-induced acute pancreatitis in inflammatory bowel diseases. Klin Farmakol Farm. 2008;22(3):110-112.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Špičák J. Etiologické faktory akutní pankreatitidy. Vnitř. Lék 2002; 48(9): 829-841.
    2. McArthur KE. Review article: drug-induced pancreatitis. Aliment Pharmacol Ther 1996; 10(1): 23-38. Go to original source... Go to PubMed...
    3. Trivedi CD, Pitchumoni CS. Drug-induced pancreatitis: an update. J Clin Gastroenterol 2005; 39(8): 709-716. Go to original source... Go to PubMed...
    4. Barthet M, Lesavre N, Desplats S, et al. Frequency and characteristics of pancreatitis in patients with inflammatory bowel disease. Pancreatology 2006; 6(5): 464-471. Go to original source... Go to PubMed...
    5. Sundström A, Blomgren K, Alfredsson L, Wiholm BE. Acid-suppressing drugs and gastroesophageal reflux disease as risk factors for acute pancreatitis - results from a Swedish Case-Control Study. Pharmacoepidemiol Drug Saf. 2006; 15(3): 141-149. Go to original source... Go to PubMed...
    6. Moolsintong P, Loftus EV Jr, Chari ST, Egan LJ, Tremaine WJ, Sandborn WJ. Acute pancreatitis in patients with Crohn's disease: clinical features and outcomes. Inflamm Bowel Dis 2005; 11(12): 1080-1084. Go to original source... Go to PubMed...
    7. Bermejo F, Lopez-Sanroman A, Taxonera C, et al. Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis. Aliment Pharmacol Ther. 2008; 28(5): 623-628. Go to original source... Go to PubMed...
    8. Rasmussen HH, Fonager K, S?rensen HT, Pedersen L, Dahlerup JF, Steffensen FH. Risk of acute pancreatitis in patients with chronic inflammatory bowel disease. A Danish 16-year nationwide follow-up study. Scand J Gastroenterol. 1999; 34(2): 199-201. Go to original source... Go to PubMed...
    9. Inoue H, Shiraki K, Okano H, et al. Acute pancreatitis in patients with ulcerative colitis. Dig Dis Sci 2005; 50(6): 1064-1067. Go to original source... Go to PubMed...
    10. Kim KH, Kim TN, Jang BI. [A case of acute pancreatitis caused by 5-aminosalicylic acid suppositories in a patient with ulcerative colitis]. Korean J Gastroenterol. 2007; 50(6): 379-383. Go to original source... Go to PubMed...
    11. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 2002; 51(4): 536-539. Go to original source... Go to PubMed...
    12. Munk EM, Pedersen L, Floyd A, N?rg?rd B, Rasmussen HH, S?rensen HT. Inflammatory bowel diseases, 5-aminosalicylic acid and sulfasalazine treatment and risk of acute pancreatitis: a population-based case-control study. Am J Gastroenterol 2004; 99(5): 884-888. Go to original source... Go to PubMed...
    13. Weersma RK, Peters FT, Oostenbrug LE, et al. Increased incidence of azathioprine-induced pancreatitis in Crohn's disease compared with other diseases. Aliment Pharmacol Ther 2004; 20(8): 843-850. Go to original source... Go to PubMed...
    14. Bajaj JS, Saeian K, Varma RR, et al. Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: a tertiary referral center experience. Am J Gastroenterol 2005; 100(5): 1121-1125. Go to original source... Go to PubMed...
    15. Marinaki AM, Ansari A, Duley JA, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 2004; 14(3): 181-187. Go to original source... Go to PubMed...
    16. Gearry RB, Roberts RL, Barclay ML, Kennedy MA. Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. Pharmacogenetics. 2004; 14(11): 779-781. Go to original source... Go to PubMed...
    17. von Ahsen N, Armstrong VW, Behrens C, et al. Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study. Clin Chem. 2005; 51(12): 2282-2288. Go to original source... Go to PubMed...
    18. Massironi S, Losco A, Basilisco G. Drug side-effects in IBD. Aliment Pharmacol Ther 2002; 16(10): 1831. Go to original source... Go to PubMed...
    19. Tsesmeli NE, Giannoulis KE, Savopoulos CG, et al. Acute pancreatitis as a possible consequence of metronidazole during a relapse of ulcerative colitis. Eur J Gastroenterol Hepatol 2007; 19(9): 805-806. Go to original source... Go to PubMed...
    20. Khanna S, Kumar A. Acute pancreatitis due to hydrocortisone in a patient with ulcerative colitis. J Gastroenterol Hepatol. 2003; 18(9): 1110-1111. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.